Predict your next investment

MedGenome Labs company logo
Corporation
HEALTHCARE | Disease Diagnosis
medgenome.com

See what CB Insights has to offer

Founded Year

2013

Stage

Series C - IV | Alive

Total Raised

$137M

Last Raised

$16.5M | 5 mos ago

About MedGenome Labs

MedGenome is a genomics-driven research and diagnostics company which decodes genetic information contained in an individual's genome. Its access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care.

MedGenome Labs Headquarter Location

348 Hatch Drive

Foster City, California, 94404,

United States

(888) 440-0954

Latest MedGenome Labs News

02:30 ET Emmes and MedGenome Launch Genomics Strategic Partnership Focused on Advancing Rare Disease Research

Nov 15, 2021

USA - English Share this article Share this article ROCKVILLE, Md., Nov. 15, 2021 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome aimed at accelerating breakthrough treatments, powered by human genomics, for rare disease patients. "This is an exciting opportunity to partner with the leading genetic testing laboratory in India and South Asia to use our collective expertise to help bring faster and more innovative treatments to patients around the world who are suffering from rare diseases and desperately awaiting new therapies," said Emmes Chief Executive Officer Dr. Christine Dingivan. "The unmatched potential to build comprehensive and curated disease specific cohorts will leverage the power of large data sets to design smarter research protocols and to reduce the time it takes to identify rare disease patients for clinical trials. Ultimately, we hope this will result in more successful treatment outcomes." During its recognition of Rare Disease Day on March 5, 2021, the U.S. Food and Drug Administration noted, "Patients with rare diseases often have few or no treatment options. In 2020, we continued to see significant progress in the development of treatments for rare diseases, also known as orphan products. "  In 2020, the FDA approved 32 novel drugs and biologics that had an orphan drug designation. Traci Clemons, Ph.D., Emmes' Chief Research Officer, explained that the two companies would collaborate to combine patients' epidemiologic, phenotypic and genomic data into custom disease registries to enhance study design, support patient recruitment, and create standard control arms for advanced statistical models of treatment effect. "There are so many rare diseases and, at the same time, a very small global pool of potential patients for these clinical trials," she said. "Creating these disease registries across high population regions will give us an even greater opportunity to identify and recruit patients with these very rare diseases into clinical trials. These cohorts will, in a sense, offer a customized data resource for potential research sponsors, from biotech firms to large pharmaceutical companies and government research institutions." Earlier this month, Emmes launched a new rare disease center, blending its expertise in biostatistics, data management and clinical research with Orphan Reach's rare disease patient and clinical trial experience. Emmes acquired the UK-based Orphan Reach in May. According to a recent article in Scientific American, "Only 5% of the 7,000 known rare diseases have an approved treatment, making patients with rare diseases collectively one of the most underserved communities in medicine today." Some of the initial rare diseases that the Emmes/MedGenome partnership will address include hemophilia, Duchenne muscular dystrophy and muscular atrophies, and retinitis pigmentosa. MedGenome Services CEO Dr. Vedam Ramprasad, said, "Few people realize that India and South Asia have the world's largest population of people affected by rare and inherited disease. Given the high unmet need of these patients and families, we are dedicated to expanding support and opportunities for the rare disease community in South Asia to contribute to, and benefit from, the substantial treatment advances being made in rare disease globally." He added, "Rare disease clinical trials face substantial recruitment and regulatory challenges globally. Our rare disease alliance with Emmes is positioned to directly mitigate these challenges and is a natural extension of MedGenome's substantial investment to support rare disease patients and clinicians in South Asia." Dr. Christine Dingivan concluded, "There is no clear CRO market leader in this space. Our acquisition of Orphan Reach, the creation of our new rare disease center, and now this strategic partnership with MedGenome, solidifies our leadership standing in rare disease drug development." About MedGenome MedGenome  is a genomics-driven research and diagnostics company with a mission to expand access to personalized medicine in South Asia and other emerging markets and help improve global health. Its unique access to genomics data matched with clinical and phenotypic data provides insights into rare and complex diseases at the genetic and molecular level to facilitate research advances and personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India. For more information, go to: https://research.medgenome.com/ About Emmes Founded in 1977, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company's clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com . SOURCE Emmes

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MedGenome Labs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MedGenome Labs is included in 5 Expert Collections, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

11,293 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

MedGenome Labs Patents

MedGenome Labs has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2017

7/16/2019

Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/23/2017

00/00/0000

Grant Date

7/16/2019

00/00/0000

Title

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins

Subscribe to see more

Status

Grant

Subscribe to see more

MedGenome Labs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MedGenome Labs Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.